A global review points to sustained growth in ADHD diagnosis and treatment
Diagnoses of attention-deficit/hyperactivity disorder are increasing across many countries and across all age groups, according to a new review summarized in the supplied source text. The same review found that prescriptions for ADHD treatments have also risen broadly, suggesting that the trend is not limited to growing recognition alone but is also changing how health systems treat the condition.
The review was published in the Journal of Psychopharmacology and brought together recently published research on ADHD diagnoses and prescriptions worldwide. That scope matters. ADHD discussions are often dominated by local anecdotes, school experiences, or country-specific debates over diagnosis rates. A cross-country review does not settle every question about prevalence, access, or treatment quality, but it does offer a clearer view of whether changes are isolated or systemic. The headline finding here is that the increase appears widespread.
The UK data show how large the shift has become
The source text gives the clearest numerical detail for the United Kingdom. Between 2000 and 2018, recorded ADHD diagnoses and treatment prescriptions increased across all age groups. The largest increase in diagnoses during that period occurred among children, which is consistent with ADHD's long-standing association with school-age populations. But the review also found a distinct increase among adults, a trend that has become increasingly important to clinicians and health systems.
Among men ages 18 to 29 in the UK, the rise was especially striking. The review found an approximately 20-fold increase in diagnoses and an almost 50-fold increase in prescriptions. Those figures do not mean ADHD suddenly emerged as a new condition in young adulthood. A more cautious reading, supported by the source text, is that diagnosis and treatment pathways changed substantially over time, bringing more adults into formal recognition and care.
The review also highlights an important shift in the sex ratio of diagnoses. In childhood and adolescence, the ratio of diagnosed ADHD cases was approximately four males for every one female. In adulthood, however, the ratio was nearly one-to-one. That change is notable because it suggests that historical diagnosis patterns may have missed or under-recognized significant numbers of girls and women earlier in life.
Recognition is widening beyond the traditional picture
The supplied source text directly points to one explanation for the changing adult and sex patterns: increased recognition of how ADHD presents in girls and adults, groups that have historically been underdiagnosed. That observation matters because the older public image of ADHD has often centered on disruptive behavior in boys, particularly in school settings. If clinicians have improved their understanding of how symptoms can present differently across age and sex, diagnosis rates may rise even without any underlying change in the disorder itself.
That does not mean every increase reflects better care, nor does it automatically mean overdiagnosis. The material provided here does not support such sweeping conclusions either way. What it does support is that health systems are identifying ADHD in populations that were previously more likely to be overlooked. The nearly equal adult diagnosis ratio between men and women is one of the strongest indicators in the supplied text that diagnostic patterns have shifted in meaningful ways.
This has practical consequences. Adult ADHD can affect work, organization, relationships, and mental health support needs. Greater recognition in adults means clinicians, employers, and public health planners may need to think beyond childhood frameworks. It also means that demand for specialist assessments and ongoing treatment could continue to rise even if childhood diagnosis rates stabilize.
Prescription growth is part of the same story
The review did not find only more diagnoses. It also found more prescribing. In England, prescriptions of central nervous system stimulants, described in the source text as the main prescription treatments for ADHD, increased by 32 percent among adults age 18 and older in 2021 to 2022. Among children under 17, prescriptions increased by 12 percent from 2022 to 2023.
One particularly important milestone emerged from those figures: it was the first time more adults than children were prescribed these drugs since records started in 2015. That is a meaningful marker because it suggests the center of gravity in ADHD treatment is changing. ADHD is still often discussed as a childhood condition, but prescribing patterns are increasingly reflecting a lifespan view of the disorder.
The review also cites a retrospective study covering more than 154 million people across 13 countries in North America, Europe, and Asia. That study found that ADHD medication use increased in those regions as well. Taken together with the UK evidence, the pattern appears broad rather than local. The rise in prescriptions is therefore not just a British administrative artifact in the material provided here. It is part of a larger international shift.
Why the increases matter
Growing diagnosis and treatment rates can mean several things at once. At a minimum, they signal that ADHD services are under heavier demand than in the past. If more adults are being evaluated and treated, health systems need enough trained clinicians, monitoring capacity, and follow-up support to handle that load responsibly. Medication management, especially for stimulants, requires continuity and oversight. Expanding access without adequate capacity can strain care quality.
The source text also points to increased public awareness as a major factor behind rising diagnoses and prescriptions. That is plausible and important. Public awareness can help people recognize symptoms and seek help. It can also change the willingness of clinicians, families, schools, and employers to take ADHD seriously. In that sense, higher diagnosis rates are not only a medical story but also a social one. They reflect a shift in recognition, language, and legitimacy.
At the same time, broad increases invite closer scrutiny from policymakers and researchers. Are services reaching the people who were previously missed? Are treatment pathways equitable across age, sex, and region? Can health systems keep up with adult demand? The supplied material does not answer those questions in full, but it makes them harder to ignore. When diagnoses and prescriptions rise across multiple countries and age groups, the issue moves beyond isolated debate and into the territory of structural healthcare planning.
A longer-term reframing of ADHD
The most important takeaway from the review may be that ADHD is increasingly being handled as a condition that spans the life course. The older assumption that it is mainly a childhood issue is less consistent with the patterns summarized in the source text. Adults are being diagnosed more often, adults are receiving more prescriptions, and women appear to be achieving greater diagnostic visibility later in life.
That reframing does not resolve every controversy around ADHD. But it does sharpen the policy and clinical question. If the world is becoming better at identifying ADHD across age groups, then systems for assessment, treatment, and support will need to evolve with that reality. The review's results suggest that this shift is already underway. The next challenge is whether healthcare infrastructure can keep pace with a condition that is no longer being seen through a childhood-only lens.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
